Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,858 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05982093RecruitingPhase 2
Elacestrant with or without triptorelin for premenopausal breast cancer
This trial tests a new hormone-blocking pill (elacestrant) with or without a shot that temporarily stops ovaries (triptorelin) for premenopausal women with early-stage, hormone-sensitive breast cancer. It aims to find a gentler treatment option before surgery.
Badalona, BarcelonaAges 35 years+ - NCT06571734RecruitingPhase 2
XL092 for advanced sarcoma types
This trial tests an experimental drug called XL092 (zanzalintinib) for people with advanced leiomyosarcoma, bone sarcoma, or translocation-associated soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is a type of targeted therapy that may stop cancer growth.
Chicago, IllinoisAges 18 years+ - NCT06681064Recruiting
Tracking breast cancer changes during pre-surgery treatment
This study looks at how breast cancer changes while you are receiving chemotherapy or targeted therapy before surgery. The goal is to better understand which treatments work best for different types of breast cancer.
LondonAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Miami, FloridaAges 18–90 - NCT06736379RecruitingPhase 1
RNA Therapy Injections for Head and Neck Cancer
This trial tests a new type of immunotherapy made of self-amplifying RNA (saRNA) that produces a protein called IL-12. It's injected directly into head and neck tumors to help your immune system fight the cancer. The study is for people whose cancer has not responded well to standard treatments or who are having surgery to remove their tumor.
Stanford, CaliforniaAges 18 years+ - NCT06781996RecruitingPhase 3
Digital tool to help manage hormone therapy side effects
This trial tests a digital tool (a smartphone app) to help women and men with early breast cancer manage side effects from hormone therapy. The goal is to improve quality of life during treatment.
VillejuifAges 18 years+ - NCT06989450Recruiting
Digital support for women on hormone therapy for breast cancer
This trial tests a smartphone app called Sidekick to help women with early-stage breast cancer stick to their hormone therapy and feel more confident managing their health. If you were diagnosed with stage I, II, or III breast cancer after September 2023 and are starting hormone therapy, this program might help you stay on track.
ReykjavikAges 18 years+ - NCT07018869RecruitingPhase 3
A website to improve follow-up care for colorectal cancer survivors
This study tests if an educational website, viewed with a supporter, can improve follow-up care for people who had surgery for stage II or III colorectal cancer. It aims to help patients and their supporters find helpful information together.
Anchorage, AlaskaAges 18 years+ - NCT07121595RecruitingPhase 2
Personalized neck radiation for mouth cancer with sentinel node biopsy
This study tests whether a personalized approach to radiation therapy after surgery, guided by a special lymph node biopsy (sentinel node biopsy), can effectively treat mouth cancer while reducing side effects. It is for people whose cancer is on one side of the mouth and has not spread to the other side of the neck or beyond.
Ann Arbor, MichiganAges 18 years+ - NCT07468903Recruiting
Focal radiation for prostate cancer with HDR brachytherapy
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Los Angeles, CaliforniaAges 40 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Birmingham, AlabamaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Birmingham, AlabamaAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT07281417RecruitingPhase 2
Testing adding cemiplimab to chemo before surgery for sinus cancer
This trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps treat sinonasal squamous cell carcinoma. The goal is to see if this combination reduces tumors more effectively than chemotherapy alone.
Irvine, CaliforniaAges 18 years+ - NCT06534125Recruiting
Acupuncture to prevent joint pain from hormone therapy in Black women
This study tests whether acupuncture can prevent joint pain caused by a common hormone therapy pill (aromatase inhibitor) in Black women who have finished treatment for early-stage breast cancer.
Atlanta, GeorgiaAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Duarte, CaliforniaAges 65 years+ - NCT03137095Recruiting
Study how chemotherapy affects brain function in breast cancer
This study looks at changes in thinking and brain function in people with early to locally advanced breast cancer before and during chemotherapy. You may also be offered a brain MRI in a separate optional part of the research to learn more about brain changes.
Rochester, New YorkAges 21 years+ - NCT06553612Recruiting
Supportive care planning after gynecological cancer treatment
This study compares a special day-hospital visit focused on supportive care needs to standard follow-up for people who have finished initial treatment for ovarian or endometrial cancer. The goal is to see if the special visit helps more people get the supportive care they need.
BesançonAges 18 years+ - NCT05786664Recruiting
Breast cancer survivor study collecting your health samples
This study invites women who finished treatment for non-metastatic invasive breast cancer to share health information and biological samples for future research. It may help scientists understand survivorship and improve care after treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT07747740RecruitingPhase 2
Bladder cancer treatment after BCG therapy fails
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
Moscow, MoscowAges 18 years+ - NCT03483337Recruiting
MRI scan tests new markers for head and neck cancers
This trial tests special MRI scans to find warning signs of cancer that has returned or spread in the head and neck area. It may help doctors see these changes more clearly, which could improve treatment planning.
New York, New YorkAges 18 years+ - NCT04277858RecruitingPhase 2
Pre-surgery chemo plus robotic surgery for p16-positive throat cancer
This trial tests whether giving chemotherapy before robotic surgery works well for certain p16-positive oropharyngeal (throat) cancers. It aims to shrink or control the cancer and allow the surgeon to remove the tumor with clean margins while avoiding cancer spread beyond the neck.
Montreal, QuebecAges 18–80 - NCT04434040RecruitingPhase 2
Atezolizumab and sacituzumab to prevent breast cancer return
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
San Francisco, CaliforniaAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,858 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.